Company: PRTA
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001559053-25-000009
Chunk: 154

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 154
---
 31, 2024 and 2023Issued and outstanding shares — none at December 31, 2024 and 2023 Ordinary shares, $0.01 par value:538 537 Authorized shares — 100,000,000 at December 31, 2024 and 2023Issued and outstanding shares — 53,826,982 and 53,682,117 at December 31, 2024 and 2023, respectivelyAdditional paid-in capital1,588,729 1,540,859 Accumulated deficit(1,102,341)(980,031)Total shareholders’ equity486,926 561,365 Total liabilities and shareholders’ equity$547,108 $696,382 

 See accompanying Notes to Consolidated Financial Statements.

77

Prothena Corporation plc and Subsidiaries

Consolidated Statements of Operations

(in thousands, except per share data)

Year Ended December 31,202420232022Collaboration revenue$135,107 $91,320 $13,855 Revenue from license and intellectual property50 50 40,050 Total revenue135,157 91,370 53,905 Operating expenses:Research and development222,519 220,571 135,562 General and administrative67,199 61,835 49,900 Total operating expenses289,718 282,406 185,462 Loss from operations(154,561)(191,036)(131,557)Other income (expense):Interest income25,816 31,014 6,349 Other expense, net(185)(458)(397)Total other income, net25,631 30,556 5,952 Loss before income taxes(128,930)(160,480)(125,605)Benefit from income taxes(6,620)(13,452)(8,656)Net loss$(122,310)$(147,028)$(116,949)Basic and diluted net loss per ordinary share$(2.27)$(2.76)$(2.47)Shares used to compute basic and diluted net loss per share53,772 53,216 47,369 

See accompanying Notes to Consolidated Financial Statements.

78

 Prothena Corporation plc and Subsidiaries

Consolidated Statements of Cash Flows

(in thousands)

Year Ended December 31,202420232022Operating activitiesNet loss